Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Keeping Track Of The US FDA's Final Approvals Of 2018

Executive Summary

A roundup of the US FDA's drug approvals in the final weeks of 2018.

Related Content

Finance Watch: VC Deals Keep Up Fast Pace With $1.1bn In Less Than Three Weeks
EU Accelerated Assessment Tracker: Nine Definites So Far From 24 Requests In 2018
First-Line Ovarian Cancer Approval Solidifies Lead For AstraZeneca's Lynparza
Stellar Survival Data For AZ's Lynparza Hailed At ESMO
Keeping Track: AstraZeneca Wins Approval For Lumoxiti, AbbVie Expands Label For Venclexta With MRD Data, and FDA Delays Acorda's Inbrijia NDA
Servier Acquires Shire Oncology Business For $2.4bn
Pfizer's Avelumab Makes Its Debut, In Rare Form Of Skin Cancer
Veloxis' Tacrolimus Clears FDA For Narrower Population Following Court Loss
FDA Exclusivity Protections Blocking ‘Me Too’ Product Challenged In Lawsuit


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts